Singapore-based Biofourmis, which claims to be the world’s first personalised physiological data analytics firm, has closed a US$ 1 million round, that was led by South African healthcare professional services provider SpesNet and Eden Strategy. The round also saw participation from other angel investors in the healthcare space.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
